ClinicalTrials.gg

Program

Ropivacaine

Also written as “TLC590”, “Ropivacaine + Clonidine + Betamethasone” and “ropivacaine”.

Its studies are mostly in Pain, Postoperative · Hernia, Inguinal · Bunion · Pain · Hallux Valgus, led by 10 companies.

Furthest: phase 3, since Nov 1, 202217 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PainReform40 open or runningphase 3since Nov 1, 2022Apr 16, 2009none ahead
Taiwan Liposome31 open or runningphase 3since Dec 3, 2021Jun 25, 2018none ahead
PHARMAFINA20 open or runningphase 2since Jul 31, 2025Jan 6, 2025none ahead
TLC Biopharmaceuticals22 open or runningphase 3since Oct 28, 2025Aug 25, 2024none ahead
AstraZeneca10 open or runningphase 3since Jul 28, 2006Jul 28, 2006none ahead
BioQ Pharma10 open or runningphase 3since Nov 4, 2016Nov 4, 2016none ahead
Cali Pharmaceuticals10 open or runningphase 2since Aug 14, 2021Aug 14, 2021none ahead
Egymedicalpedia10 open or runningphase 1since Sep 13, 2022Sep 13, 2022none ahead
Jiangsu HengRui Medicine11 open or runningphase 2since Sep 27, 2022Sep 27, 2022none ahead
Vital 510 open or runningno phasesince Oct 27, 2014Oct 27, 2014none ahead

Also a collaborator on its studies: monitorcro.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jul 28, 2006.

  1. Oct 27, 2014Vital 5's first study: no phase study in Low Back PainNew to Vital 5Vital 5 · NCT02293525
  2. May 24, 2016Phase 2 study in Pain, PostoperativePainReform · NCT02784327 · 15 enrolled · Israel
  3. Nov 4, 2016BioQ Pharma's first study: phase 3 study in Pain, PostoperativeNew to BioQ PharmaBioQ Pharma · NCT02959476 · 132 enrolled · United States
  4. Jun 25, 2018Taiwan Liposome's first study: phase 2 study in Hernia, InguinalNew to Taiwan LiposomeTaiwan Liposome · NCT03591146 · 65 enrolled · United States
  5. Feb 11, 2019Phase 2 study in Hallux ValgusTaiwan Liposome · NCT03838133 · 150 enrolled · United States
  6. Aug 14, 2021Cali Pharmaceuticals's first study: phase 2 study in Inguinal HerniorrhaphyNew to Cali PharmaceuticalsCali Pharmaceuticals · NCT05080959 · 105 enrolled · United States
  7. Dec 3, 2021Phase 3 study in Postsurgical Pain ManagementTaiwan Liposome · NCT05161637 · 415 planned
  8. Sep 13, 2022Egymedicalpedia's first study: phase 1 study in Hernia, InguinalNew to EgymedicalpediaEgymedicalpedia · NCT05549492 · 64 enrolled · Egypt
  9. Sep 27, 2022Jiangsu HengRui Medicine's first study: phase 2 study in Total Knee ArthroplastyNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05561309 · 89 enrolled · China
  10. Nov 1, 2022Phase 3 study in BunionPainReform · NCT05773846 · 428 enrolled · United States
  11. Aug 25, 2024TLC Biopharmaceuticals's first study: phase 2 study in Postsurgical Pain ManagementNew to TLC BiopharmaceuticalsTLC Biopharmaceuticals · NCT06574269 · 120 planned · United States
  12. Jan 6, 2025PHARMAFINA's first study: phase 1 study in HealthyNew to PHARMAFINAPHARMAFINA · NCT06781632 · 12 enrolled · Turkey
  13. Jul 31, 2025Phase 2 study in Nerve BlockPHARMAFINA · NCT07131657 · 40 enrolled · Turkey (Türkiye)
  14. Oct 28, 2025Phase 3 study in Pain, PostoperativeTLC Biopharmaceuticals · NCT07222748 · 304 enrolled · United States

TargetBeta

“Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07222748Pain, Postoperative · United States3Active, not recruitingTLC BiopharmaceuticalsJun 12, 2026304
NCT07131657Nerve Block · Turkey (Türkiye)2CompletedPHARMAFINADec 3, 202540
NCT06781632Healthy · Turkey1CompletedPHARMAFINAFeb 20, 202512
NCT06574269Postsurgical Pain Management · United States2RecruitingTLC BiopharmaceuticalsJul 2026120
NCT05773846Bunion · United States3CompletedPainReformJul 30, 2024428
NCT05561309Total Knee Arthroplasty · China2Active, not recruitingJiangsu HengRui MedicineDec 202489
NCT05549492Hernia, Inguinal · Egypt1CompletedEgymedicalpediaMay 1, 202264
NCT05161637Postsurgical Pain Management3Not yet recruitingTaiwan LiposomeDec 2025415
NCT05080959Inguinal Herniorrhaphy · United States2CompletedCali PharmaceuticalsDec 31, 2021105
NCT03838133Hallux Valgus · United States2CompletedTaiwan LiposomeMar 31, 2020150
NCT03591146Hernia, Inguinal · United States2CompletedTaiwan LiposomeJan 5, 201965
NCT02959476Pain, Postoperative · United States3CompletedBioQ PharmaAug 10, 2018132
NCT02784327Pain, Postoperative · Israel2UNKNOWNPainReformApr 201715
NCT02293525Low Back Pain–WithdrawnVital 5Jan 20160
NCT01681966Pain, Postoperative · Israel2CompletedPainReformMay 4, 201615
NCT00883194Pain · Israel2CompletedPainReformApr 201115
NCT00358280Anesthesia,Spinal · China3CompletedAstraZeneca220

How it is read

Names in the registry

  • “TLC590”, 10 entries
  • “Ropivacaine”, 4 entries
  • “Ropivacaine + Clonidine + Betamethasone”, 3 entries
  • “ropivacaine”, 1 entry
  • “HR18034;Ropivacaine Hydrochloride Injection”, 1 entry

Codes read as this program: PRF110.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.